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Introduction {#sec1}
============

Mesenchymal stem/stromal cells (MSCs) have putative roles of safeguarding adult tissue/organ homeostasis and maintaining regenerative tissue repair, the *in vivo* characteristics of which regarding their specific identity, specialized niches, and the associated function are hot topics in this field ([@bib17]; [@bib24]). Particularly, over the years, the notion that postnatal MSCs reside adjacent to the vasculature has attracted much research interest ([@bib7]; [@bib9]; [@bib32]). In 2014, researchers demonstrated that glioma-associated oncogene homolog 1 (Gli1) marks perivascular MSC-like cells in the mouse incisor, which express typical MSC surface markers and possess multiple differentiation potentials in culture ([@bib45]). During the past several years, accumulating evidence suggests that Gli1^+^ cells are present in various organs where they are embedded in adventitial matrix or make close contact to microvascular endothelial cells (ECs), and possess important biological functions. In this regard, Gli1^+^ cells represent a subpopulation of MSCs across many organs that are characterized by perivascular location ([@bib19], [@bib18]; [@bib30]; [@bib33]). Notably, MSCs have been documented to stimulate angiogenesis *in vitro* and in cytotherapy or tissue engineering applications ([@bib16]; [@bib25]; [@bib27]). However, whether and how the perivascular localization of specific MSCs, in particular Gli1^+^ cells, affects angiogenesis *in situ* remains unclear.

Recent studies have established a specific capillary subtype in bone, namely type H vessels, which are featured by CD31^hi^Endomucin (EMCN)^hi^ markers with an interconnected straight column pattern and high proliferative capacity ([@bib20]; [@bib28]). On the other hand, the terminology type L vessels were proposed for the CD31^lo^EMCN^lo^ sinusoidal vessels. Notably, type H vessels are upstream of type L vessels, and mediate developmental and regenerative angiogenesis in bone ([@bib20]; [@bib28]). Moreover, compared with type L vessels, type H vessels exclusively connect to arteries and possess functional properties to maintain perivascular osteoprogenitors and couple angiogenesis to osteogenesis ([@bib20]). Importantly, the type H endothelium has been revealed as a crucial mediator of bone regeneration and a pharmacological target to counteract bone loss and enhance fracture healing ([@bib20]; [@bib42]). Mechanistically, a series of cellular and molecular basis has been reported to regulate type H vessel formation ([@bib4]; [@bib11]; [@bib28]; [@bib41]; [@bib42]; [@bib43]). Nevertheless, the MSC-mediated regulation of type H vessels is not clear. Despite studies claiming that type H and the type L endothelium might be associated with differential subsets of MSCs, evidence is lacking to identify the specific subpopulations of MSCs coupling with and regulating specialized vessel subtypes ([@bib21]; [@bib34]; [@bib48]).

Here, we show that Gli1^+^ cells represent a subpopulation of MSCs that couple with and regulate type H vessel formation. As the preferable vasculature where Gli1^+^ cells are adjacently localized, type H capillaries have close functional correlation with Gli1^+^ cells in bone growth and defect healing processes. Genetic ablation experiments further identified that Gli1^+^ cells contribute to type H vessel formation which is indispensable for bone homeostasis and healing. In addition, cellular and molecular investigations suggested that Gli and hypoxia inducible factor-1 alpha (HIF-1α) signaling are involved in Gli1^+^ cell-mediated regulation of angiogenesis. These findings suggest a functional framework that Gli1^+^ cells drive the formation of the neighboring specialized vasculature for tissue generation and repair.

Results {#sec2}
=======

Gli1^+^ Cells Are Spatially Coupled with Type H Vessels {#sec2.1}
-------------------------------------------------------

While Gli1^+^ cells contribute to bone homeostasis ([@bib19]; [@bib30]; [@bib33]), we hereby use *Gli1-LacZ* mice ([@bib44]) to characterize the locational correlation between Gli1^+^ cells and vessels in bone. In the meanwhile, we have used CD105, neuron-glial antigen 2 (NG2), CD146, and stem cell antigen 1 (SCA1) as the putative *in vivo* MSC marker combination ([@bib45]). We found that Gli1^+^ cells expressed these markers ([Figure 1](#fig1){ref-type="fig"}A), and are located adjacent to CD31^+^ ECs ([Figure 1](#fig1){ref-type="fig"}A), further confirming Gli1^+^ cell identity as a specific subpopulation of MSCs located in the skeletal perivascular niche ([@bib19]; [@bib30]; [@bib33]). Considering that type H vessels are recognized as a specific vessel subtype upstream of type L vessels and supporting skeletal formation and regeneration ([@bib20]; [@bib28]), we hereby focused on the cellular distribution adjacent to distinct types of blood vessels in bone ([Figure S1](#mmc1){ref-type="supplementary-material"}). We first examined the association of the putative *in vivo* MSC markers with type H vessels and observed preferential colocation of these markers with the CD31^hi^EMCN^hi^ type H endothelium, which were essentially absent from the vicinity of CD31^lo^EMCN^lo^ type L vessels ([Figures 1](#fig1){ref-type="fig"}B--1F), suggesting spatial correlation of MSCs and type H vessels. Notably, further exploration on Gli1^+^ cells demonstrated that, in the femoral metaphyseal region close to the growth plate, Gli1^+^ cells preferably resided with type H endothelium ([Figure 1](#fig1){ref-type="fig"}G). Quantification analysis also confirmed that metaphyseal Gli1^+^ cells were distributed particularly close to the type H vasculature, rather than the type L vessels ([Figure 1](#fig1){ref-type="fig"}H) ([@bib20]). Furthermore, the selective position of Gli1^+^ cells around the type H vessels was also identified in the diaphyseal region ([Figures 1](#fig1){ref-type="fig"}G and 1H). These findings indicated that Gli1^+^ cells represented a subpopulation of MSCs that are spatially correlated with type H vessels.Figure 1Gli1^+^ Cells are Spatially Coupled with Type H Vessels in Bone(A) β-Galactosidase (β-gal) immunostaining showing Gli1-LacZ^+^ cells (green), CD31 (white), and CD105, NG2, CD146, or SCA1 (red) co-immunostaining in the femoral metaphysis of 4-week-old *Gli1-LacZ* mice. Dotted lines outline margins of growth plates in the metaphysis. The boxed areas are shown magnified in the bottom images. Scale bars, 100 μm.(B) CD105 (white), CD31 (green), and EMCN (red) co-immunostaining in the femoral metaphysis of 4-week-old *Gli1-LacZ* mice counterstained by Hoechst (blue). Dotted lines outline margins of growth plates in the metaphysis. Scale bars, 100 μm.(C) NG2 (white), CD31 (green), and EMCN (red) co-immunostaining in the femoral metaphysis of 4-week-old *Gli1-LacZ* mice counterstained by Hoechst (blue). Dotted lines outline margins of growth plates in the metaphysis. Scale bars, 100 μm.(D) CD146 (white), CD31 (green), and EMCN (red) co-immunostaining in the femoral metaphysis of 4-week-old *Gli1-LacZ* mice counterstained by Hoechst (blue). Dotted lines outline margins of growth plates in the metaphysis. Scale bars, 100 μm.(E) SCA1 (white), CD31 (green), and EMCN (red) co-immunostaining in the femoral metaphysis of 4-week-old *Gli1-LacZ* mice counterstained by Hoechst (blue). Dotted lines outline margins of growth plates in the metaphysis. Scale bars, 100 μm.(F) Quantification of percentages of CD105^+^, NG2^+^, CD146^+^, and SCA1^+^ cells adjacent to type H and type L vessels. n = 3 mice per group.(G) β-Gal immunostaining showing Gli1-LacZ^+^ cells (white) with CD31 (green) and EMCN (red) co-immunostaining in the femoral metaphysis and diaphysis of 4-week-old *Gli1-LacZ* mice counterstained by Hoechst (blue). Dotted lines outline margins of growth plates in the metaphysis. The boxed areas are shown magnified on the right. Scale bars, 100 μm.(H) Quantification of percentages of Gli1-LacZ^+^ cells adjacent to type H and type L vessels in the metaphysis and diaphysis of 4-week-old *Gli1-LacZ* mice. n = 5 mice per group.^∗∗∗^p \< 0.0001. Data are presented as mean ± SD. See also [Figure S1](#mmc1){ref-type="supplementary-material"}.

Gli1^+^ Cells Are Phenotypically Coupled with Type H Vessels in Bone Growth {#sec2.2}
---------------------------------------------------------------------------

To investigate whether Gli1^+^ cells and type H vessels were phenotypically coupled, we took a detailed look at their changes in the bone mass accrual process. We discovered that, in both metaphyseal and diaphyseal regions, there were more Gli1^+^ cells in juvenile (4-week-old) individuals compared with adult (8-week-old) compartments ([Figures 2](#fig2){ref-type="fig"}A--2D), with synergistic changes of type H vessels, rather than the type L vasculature ([Figures 2](#fig2){ref-type="fig"}A--2D). Phenotypic correlation of Gli1^+^ cells and type H vessels were additionally confirmed by flow cytometric analysis, in which the frequencies of both Gli1^+^ cells and type H ECs in total bone cells dropped in adults ([Figure 2](#fig2){ref-type="fig"}E). Similar changes were detected in the putative *in vivo* MSC marker-labeled cells ([Figures S2](#mmc1){ref-type="supplementary-material"}A--S2F). These phenomena were related to declined osteogenesis in the adult bone compared with the juvenile bone ([@bib20]), as verified by the decline of osteoprogenitor marker Runt-related transcription factor 2 (RUNX2) ([Figures S2](#mmc1){ref-type="supplementary-material"}G and S2H). Collectively, these results suggested a specific biological pattern that Gli1^+^ cells represented a subpopulation of MSCs that were phenotypically coupled with the type H vasculature in bone growth.Figure 2Gli1^+^ Cells are Phenotypically Coupled with Type H Vessels in Bone Growth(A) β-Gal immunostaining showing Gli1-LacZ^+^ cells (white) with CD31 (green) and EMCN (red) co-immunostaining in the femoral metaphysis of juvenile (4-week old) and adult (8-week old) *Gli1-LacZ* mice counterstained by Hoechst (blue). Dotted lines outline margins of growth plates in the metaphysis. Scale bars, 100 μm.(B) Quantification of fold changes of Gli1-LacZ^+^ cells, type H vessels, and type L vessels in the metaphysis of juvenile and adult *Gli1-LacZ* mice. n = 4 mice per group.(C) β-Gal immunostaining showing Gli1-LacZ^+^ cells (white) with CD31 (green) and EMCN (red) co-immunostaining in the femoral diaphysis of juvenile and adult *Gli1-LacZ* mice counterstained by Hoechst (blue). Scale bars, 100 μm.(D) Quantification of fold changes of Gli1-LacZ^+^ cells, type H vessels, and type L vessels in the diaphysis of juvenile and adult *Gli1-LacZ* mice. n = 4 mice per group.(E) Flow cytometric analysis of percentages of Gli1-tdTomato^+^ cells in total bone cells of juvenile and adult bigenic *Gli1-CreER*^*T2*^*;mT/mG* mice receiving tamoxifen (100 μg/g i.p*.* daily, three times; mice sacrificed 3 days after the last injection), and percentages of CD31^hi^EMCN^hi^ type H ECs in total bone cells of juvenile and adult mice. n = 5 mice per group.^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.0001; NS, p \> 0.05. Data are presented as mean ± SD. See also [Figure S2](#mmc1){ref-type="supplementary-material"}.

Gli1^+^ Cells Emerge and Guide Type H Vessels in Bone Defect Healing {#sec2.3}
--------------------------------------------------------------------

Next, we examined whether Gli1^+^ cells and type H vessels were functionally linked. We established a bone defect healing model ([@bib31]), and discovered an outburst appearance of Gli1^+^ cells in the healing area compared with the undefective adult diaphysis at 2 weeks after the modeling, which was accompanied by a dramatic increase of type H vessels ([Figures 3](#fig3){ref-type="fig"}A--3C). Gli1^+^ cells were also associated with RUNX2-labeled osteoprogenitors in the healing defect region, suggesting participation in the osteogenesis process ([Figure 3](#fig3){ref-type="fig"}D). Importantly, the emerged Gli1^+^ cells were distributed mainly surrounding the type H endothelium ([Figures 3](#fig3){ref-type="fig"}A--3C). Quantification analysis confirmed the remarkable upregulation of Gli1^+^ cells and type H vessels ([Figure 3](#fig3){ref-type="fig"}E), as well as the spatial coupling between Gli1^+^ cells and type H vessels during defect healing ([Figure 3](#fig3){ref-type="fig"}F). Similar changes were detected in the putative *in vivo* MSC marker-labeled cells ([Figure S3](#mmc1){ref-type="supplementary-material"}).Figure 3Gli1^+^ Cells Emerge and Guide Type H Vessels in Bone Defect Healing(A) β-Gal immunostaining showing Gli1-LacZ^+^ cells (white) with CD31 (green) and EMCN (red) co-immunostaining in femoral diaphysis from 10-week-old *Gli1-LacZ* mice without defects (Ctrl) or with healing defects at 2 weeks after femoral defect modeling counterstained by Hoechst (blue). Scale bars, 100 μm.(B) β-Gal immunostaining showing Gli1-LacZ^+^ cells (white) with CD31 (green) and EMCN (red) co-immunostaining in non-defective (Ctrl mice) or defect healing area (mice with defect modeling) counterstained by Hoechst (blue). Scale bars, 100 μm.(C) Representative β-gal immunostaining showing Gli1-LacZ^+^ cells (white) with CD31 (green) and EMCN (red) co-immunostaining in healing defect areas of *Gli1-LacZ* mice counterstained by Hoechst (blue). Scale bars, 100 μm.(D) Representative β-gal immunostaining showing Gli1-LacZ^+^ cells (green) with co-immunostaining of CD31 (white) and osteogenic marker RUNX2 (red) in healing defect areas of *Gli1-LacZ* mice counterstained by Hoechst (blue). Scale bars, 100 μm.(E) Quantification of fold changes of Gli1-LacZ^+^ cells, type H vessels, and type L vessels in Ctrl and healing area at 2 weeks after femoral defect modeling. n = 3--4 mice per group.(F) Quantification of percentages of Gli1^+^ cells adjacent to type H and type L vessels in healing areas at 2 weeks after femoral defect modeling. n = 3--4 mice per group.(G) β-Gal immunostaining showing Gli1-LacZ^+^ cells (white) with CD31 (green) and EMCN (red) co-immunostaining in healing defect areas of *Gli1-LacZ* mice at indicated time points after femoral defect modeling counterstained by Hoechst (blue). Scale bars, 100 μm.(H) Quantification of fold changes of Gli1-LacZ^+^ cells, type H vessels, and type L vessels in healing area during the healing time course. n = 3 mice per group.^∗∗^p \< 0.01; ^∗∗∗^p \< 0.0001; NS, p \> 0.05. Data are presented as mean ± SD. See also [Figure S3](#mmc1){ref-type="supplementary-material"}.

To get a clue on how Gli1^+^ cells and the type H endothelium were correlated, we performed a time course experiment in which we focused on the early phase of femoral defect healing, e.g., 3, 9, and 24 h, and 3 and 7 days, after establishment of the defect model, according to previous studies ([@bib6]; [@bib38]). As shown, as early as 9 h after defect modeling, Gli1^+^ cells appeared in the granulated tissue, while type H vessels emerged at the edge of the defect region ([Figure 3](#fig3){ref-type="fig"}G). At 24 h and 3 days, type H vessels grew toward the healing area, and at 7 days both Gli1^+^ cells and the type H endothelium were abundant in the healing defect region ([Figure 3](#fig3){ref-type="fig"}G). Statistical analysis confirmed the significant upregulation of Gli1^+^ cells and type H vessels in the early time course of bone healing, during which changes of Gli1^+^ cells occurred before type H vessels ([Figure 3](#fig3){ref-type="fig"}H). Notably, the fold change of type H vessel density could reach to higher than 25, while that of type L vessel density stayed lower than 4 ([Figure 3](#fig3){ref-type="fig"}H), indicating substantial formation of type H vessels. These data indicated that Gli1^+^ cells emerge and guide the type H vasculature formation in bone healing.

Gli1^+^ Cells Are Indispensable for Type H Vessel Formation in Bone Growth {#sec2.4}
--------------------------------------------------------------------------

To decipher whether Gli1^+^ cells indeed regulated the angiogenesis of type H vessels, we generated *Gli1-CreER*^*T2*^*;iDTA* mice and injected them with tamoxifen at one month of age ([Figure 4](#fig4){ref-type="fig"}A). As proved previously ([@bib44]), tamoxifen administration caused successful ablation of Gli1^+^ cells in bone, which was verified by quantitative real-time PCR and western blotting analyses ([Figure S4](#mmc1){ref-type="supplementary-material"}A and S4B). Similarly, cells labeled by the putative *in vivo* MSC markers were significantly reduced ([Figures 4](#fig4){ref-type="fig"}B and 4C and [Figure S4](#mmc1){ref-type="supplementary-material"}C--S4F). Four days after the last dose of tamoxifen injection, we observed a sharp decline of type H vessels in both the metaphyseal and the diaphyseal regions, suggesting the sensitivity of the type H endothelium to Gli1^+^ cell alterations ([Figures 4](#fig4){ref-type="fig"}D--4G). Type L vessels, on the other hand, showed upregulation, which was a kind of compensatory behavior taking over the original place of type H vessels ([Figures 4](#fig4){ref-type="fig"}D--4G). The dramatic decline of type H vessels was further accompanied by remarkable loss of RUNX2^+^ osteoprogenitors ([Figures 4](#fig4){ref-type="fig"}D--4G), leading to inhibition of bone mass accrual ([Figure S5](#mmc1){ref-type="supplementary-material"}A) with reduced bone volume over tissue volume (BV/TV) and trabecular numbers (Tb.N) after Gli1^+^ cell ablation ([Figure S5](#mmc1){ref-type="supplementary-material"}B). Furthermore, the HIF-1α pathway has been reported to coordinate angiogenesis during skeletal development and promote type H vessel formation in postnatal bone while the cellular origin remains unclear ([@bib20]; [@bib40]). In this regard, we explored the changes of HIF-1α expression and found that Gli1^+^ cell ablation led to significant suppression of HIF-1α signaling ([Figure 4](#fig4){ref-type="fig"}H), suggesting that HIF-1α signaling was regulated by Gli1^+^ cells, which might underlie Gli1^+^ cell-mediated modulation of type H vessels.Figure 4Gli1^+^ Cells are Indispensable for Type H Vessel Formation in Bone Growth(A) Schematic diagram showing experimental design to analyze skeletal effects of Gli1^+^ cell ablation.(B) CD31 (green), EMCN (red), and the putative *in vivo* MSC markers (white) co-immunostaining in the femoral metaphysis of Ctrl and Gli1^+^ cell ablated mice. Dotted lines outline margins of growth plates in the metaphysis. Scale bars, 100 μm.(C) Quantification of fold changes of CD105^+^, NG2^+^, CD146^+^, and SCA1^+^ cells in the metaphysis of Ctrl mice against Gli1^+^ cell ablated mice. n = 3--4 mice per group.(D) CD31 (green), EMCN (red), and RUNX2 (white) co-immunostaining in the femoral metaphysis of Ctrl and Gli1^+^ cell ablated mice counterstained by Hoechst (blue). Dotted lines outline margins of growth plates in the metaphysis. Scale bars, 100 μm.(E) Quantification of fold changes of type H vessels, type L vessels, and RUNX2^+^ cells in the metaphysis of Ctrl against Gli1^+^ cell ablated mice. n = 6 mice per group.(F) CD31 (green), EMCN (red), and RUNX2 (white) co-immunostaining in femoral diaphysis of Ctrl and Gli1^+^ cell ablated mice counterstained by Hoechst (blue). Scale bars, 100 μm.(G) Quantification of fold changes of type H vessels, type L vessels, and RUNX2^+^ cells in the diaphysis of Ctrl against Gli1^+^ cell ablated mice. n = 6 mice per group.(H) HIF-1α (red) immunostaining in the femoral metaphysis and diaphysis of Ctrl and Gli1^+^ cell ablated mice counterstained by Hoechst (blue). Dotted lines outline margins of growth plates in the metaphysis. Scale bars, 100 μm. Quantification of fold changes of HIF-1α in the metaphysis and diaphysis of Ctrl against Gli1^+^ cell ablated mice. n = 3 mice per group.^∗∗^p \< 0.01, ^∗∗∗^p \< 0.0001. Data are presented as mean ± SD. See also [Figures S4](#mmc1){ref-type="supplementary-material"} and [S5](#mmc1){ref-type="supplementary-material"}.

Genetic Ablation of Gli1^+^ Cells Leads to Reduced Type H Vessels during Bone Healing {#sec2.5}
-------------------------------------------------------------------------------------

Next, we investigated the functional importance of Gli1^+^ cell-mediated regulation of type H vessel formation in bone healing by establishing femoral defect model in *Gli1-CreER*^*T2*^*;iDTA* mice ([Figure 5](#fig5){ref-type="fig"}A). Data demonstrated that Gli1^+^ cell ablation led to dramatic suppression of the putative *in vivo* MSC markers in healing defects ([Figures 5](#fig5){ref-type="fig"}B and 5C), supporting the efficacy of Gli1^+^ cell deletion. As to the changes of type H vessels, during the early phase of femoral defect healing, e.g., 9 and 24 h after defect modeling, Gli1^+^ cell ablation significantly inhibited the growth of type H vessels toward the healing area ([Figure 5](#fig5){ref-type="fig"}D). We then made further analysis at 3 weeks after defect when, according to previous results, there was an outburst co-appearance of Gli1^+^ cells and type H vessels in wild-type mice. Results revealed that loss of Gli1^+^ cells significantly impaired type H vessel upregulation in the defect region during healing, with diminished RUNX2^+^ osteoprogenitors ([Figure 5](#fig5){ref-type="fig"}E). Statistical analysis further confirmed Gli1^+^ cell ablation-mediated inhibition of type H vessel formation ([Figures 5](#fig5){ref-type="fig"}F and 5G). Also, the expression of HIF-1α was diminished in the defect region during healing ([Figure 5](#fig5){ref-type="fig"}H). As a result, loss of Gli1^+^ cells remarkably repressed bone defect healing ([Figure S5](#mmc1){ref-type="supplementary-material"}C), as proved by reduced BV/TV and Tb.N in the healing defect area ([Figure S5](#mmc1){ref-type="supplementary-material"}D). The above findings together indicated that Gli1^+^ cells were indispensable for type H vessel formation to promote bone regeneration. Moreover, we also investigated the effects of Gli1^+^ cell deletion on skin, which possesses abundant vessels and depends on angiogenesis for wound healing. We established a cutaneous wound healing model in *Gli1-CreER*^*T2*^*;iDTA* mice and detected the changes of type H vessels. Compared with control mice, loss of Gli1^+^ cells inhibited the repair of the wound and the formation of type H vessels in the wound healing area ([Figure S6](#mmc1){ref-type="supplementary-material"}), further supporting the role of Gli1^+^ cells in promoting regenerative type H vessel formation.Figure 5Genetic Ablation of Gli1^+^ Cells Leads to Reduced Type H Vessels during Bone Healing(A) Schematic diagram showing experimental design to analyze bone defect healing after Gli1^+^ cell ablation.(B) CD31 (green), EMCN (red), and putative *in vivo* MSC markers (white) co-immunostaining in healing defect areas of Ctrl and Gli1^+^ cell ablated mice. Scale bars, 100 μm.(C) Quantification of fold changes of CD105^+^, NG2^+^, CD146^+^, and SCA1^+^ cells in healing defect areas of Ctrl and Gli1^+^ cell ablated mice. n = 3--4 mice per group.(D) CD31 (green) and EMCN (red) co-immunostaining in healing defect areas of Ctrl and Gli1^+^ cell ablated mice at 9 and 24 h after femoral defect modeling counterstained by Hoechst (blue). Scale bars, 100 μm.(E) CD31 (green), EMCN (red), and RUNX2 (white) co-immunostaining in healing defect areas of Ctrl and Gli1^+^ cell ablated mice at 3 weeks after femoral defect modeling counterstained by Hoechst (blue). Scale bars, 100 μm.(F) Quantification of fold changes of type H vessels in healing defect areas of Ctrl against Gli1^+^ cell ablated mice at 9 and 24 h after femoral defect modeling. n = 3 mice per group.(G) Quantification of fold changes of type H vessels and RUNX2^+^ cells in healing defect areas of Ctrl against Gli1^+^ cell ablated mice at 3 weeks after femoral defect modeling. n = 4--5 mice per group.(H) HIF-1α (red) immunostaining in healing defect areas of Ctrl and Gli1^+^ cell ablated mice at 3 weeks after femoral defect modeling counterstained by Hoechst (blue). Scale bars, 100 μm. Quantification of fold changes of HIF-1α in healing defect areas of Ctrl against Gli1^+^ cell ablated mice. n = 3 mice per group.^∗∗^p \< 0.01, ^∗∗∗^p \< 0.0001. Data are presented as mean ± SD. See also [Figures S5](#mmc1){ref-type="supplementary-material"} and [S6](#mmc1){ref-type="supplementary-material"}.

Gli1^+^ Cells through HIF-1α Signaling Regulate Endothelial Angiogenesis {#sec2.6}
------------------------------------------------------------------------

To directly evaluate whether Gli1^+^ cells were responsible for promoting angiogenesis and to dissect the molecular basis of Gli1^+^ cell-mediated regulation of type H vessels, we performed the *in vitro* tube formation assay ([@bib41]). We discovered that co-culture with bone marrow MSCs indeed improved tube and branch formation of ECs, whereas the effects were barely detected when using MSCs isolated from Gli1^+^ cell ablated mice that lack the subpopulation of Gli1^+^ cells ([Figures 6](#fig6){ref-type="fig"}A and 6B), suggesting that Gli1^+^ cells are indispensable for regulating endothelial angiogenesis. Besides, the pro-angiogenic effects of MSCs were significantly restrained by pretreating MSCs with Gli antagonist 61 (GANT61), a specific Gli protein inhibitor ([@bib30]) ([Figures 6](#fig6){ref-type="fig"}A and 6B), which indicated involvement of Gli signaling in Gli1^+^ cell-mediated angiogenic regulation. Furthermore, we explored the involvement of the HIF-1α pathway by pretreating MSCs with deferoxamine mesylate (DFM), which enhances stability and activity of HIF-1α ([@bib20]), and PX-478, an inhibitor of HIF-1α ([@bib1]), respectively. Results demonstrated that DFM pretreatment improved the effects of MSCs on promoting angiogenesis, while PX-478 showed suppressive action ([Figures 6](#fig6){ref-type="fig"}C and 6D). More importantly, further experiments confirmed that, for MSCs isolated from Gli1^+^ cell-depleted mice, DFM pretreatment failed to improve the pro-angiogenic effects, indicating that HIF-1α signaling plays a role in mediating the pro-angiogenic effects of Gli1^+^ cells ([Figures 6](#fig6){ref-type="fig"}E and 6F). Collectively, the evidence suggested that Gli1^+^ cells, through Gli and HIF-1α signaling, contributed to type H vessel angiogenesis ([Figure 6](#fig6){ref-type="fig"}G).Figure 6Gli1^+^ Cells through HIF-1α Signaling Regulate Endothelial Angiogenesis(A) *In vitro* tube formation by EC, EC co-cultured with MSCs from Ctrl mice, EC co-cultured with MSCs from Gli1^+^ cell ablated mice, and EC co-cultured with GANT61 (10 μM for 48 h, Gli signaling inhibition)-pretreated MSCs. Scale bars, 100 μm.(B) Quantification of cumulative tube and branching lengths. n = 4 independent experiments.(C) *In vitro* tube formation by EC co-cultured with MSCs from Ctrl mice and EC co-cultured with DFM (10 μM for 48 h, HIF-1α stabilizer and activator)-pretreated MSCs. Scale bars, 100 μm. Cumulative tube and branching lengths were quantified. n = 5 independent experiments.(D) *In vitro* tube formation by EC co-cultured with MSCs from Ctrl mice and EC co-cultured with PX-478 (10 μM for 48 h, HIF-1α inhibitor)-pretreated MSCs. Scale bars, 100 μm. Cumulative tube and branching lengths were quantified. n = 5 independent experiments.(E) *In vitro* tube formation by EC co-cultured with MSCs from Ctrl mice, EC co-cultured with DFM-pretreated MSCs, EC co-cultured with MSCs from Gli1^+^ cell ablated mice, and EC co-cultured with DFM-pretreated MSCs from Gli1^+^ cell ablated mice. Scale bars, 100 μm.(F) Quantification of cumulative tube and branching lengths. n = 5 independent experiments.(G) Diagram showing the synopsis of the findings.^∗∗^p \< 0.01, ^∗∗∗^p \< 0.0001; NS, p \> 0.05. Data are presented as mean ± SD.

Discussion {#sec3}
==========

Postnatal MSCs reside in the perivascular niche, maintain tissue homeostasis, and safeguard tissue repair, whereas little is known about whether and how their perivascular localization and angiogenesis-regulatory function are linked ([@bib7]; [@bib17]; [@bib24]). Gli1 identifies a subpopulation of MSCs particularly in bone ([@bib19]; [@bib30]; [@bib33]), where the specialized type H vessels have been recently recognized to support skeletal formation and regeneration ([@bib20]; [@bib28]; [@bib42]). In this study, we discovered that Gli1^+^ cells were preferentially localized adjacent to type H vessels in bone; Gli1^+^ cells and type H vessels further possessed close functional correlation in the bone growth and defect healing processes. Importantly, Gli1^+^ cells were revealed to be essential for type H vessel formation in bone homeostasis and healing. These findings suggest a functional framework that the Gli1^+^ subpopulation of MSCs drives formation of the coupled specialized vasculature for tissue generation and repair.

Postnatal MSCs play a role in tissue homeostasis, the *in vivo* identity of which associated with their specific function remains as a research focus ([@bib17]; [@bib24]). Particularly in bone, a typical reservoir of MSCs, lineage-tracing studies have indicated subpopulations of MSCs marked by Nestin, Leptin receptor (LepR), among others, mediating skeletal and hematopoietic maintenance ([@bib26]; [@bib48]). Among them, Gli1 especially defines a subpopulation of MSCs characterized by perivascular location which contribute to bone formation and injury repair ([@bib19]; [@bib30]; [@bib33]). Accordingly, targeting skeletal MSCs to facilitate bone regeneration holds promise for counteracting bone loss and promoting defect and fracture healing ([@bib37]; [@bib47]). In this study, we revealed that Gli1^+^ cells, which expressed the putative *in vivo* MSC markers, are upstream of specialized type H vessels. The type H vessels are identified with distinct functional properties to couple angiogenesis to osteogenesis and mediate bone generation ([@bib20]; [@bib28]). Anatomically, arteries exclusively connect to type H vessels in the metaphysis and endosteum while they do not deliver blood directly into type L sinusoidal capillaries. Thus distinct trophic and oxygenous microenvironments can be detected in different vascular regions of the postnatal long bone ([@bib20]; [@bib28]). Consequently, the type H vasculature, together with the released growth factors by type H ECs, supports an appropriate niche for osteoprogenitors in skeletal growth and repair ([@bib20]; [@bib28]; [@bib42]). In this study, we unraveled an intriguing role of Gli1^+^ cells to guide and initiate type H vessel angiogenesis during bone growth and healing. Besides, we also revealed that Gli1^+^ cells were essential for type H vessel formation in skin wound healing which depends on angiogenesis for regenerative repair. Considering that Gli1^+^ cells exist in multiple organs ([@bib19]) and different organs have heterogeneous vasculature ([@bib15]), it remains interesting to investigate whether MSC-mediated regulation of specialized angiogenesis underlies tissue development and regeneration across the organism. In addition, Gli1^+^ cells have been identified as MSCs in human bone marrow via immunostaining and *in vitro* culture, comparable with the findings in murine bone marrow. More importantly, Gli1^+^ cells were revealed to expand in patients with bone marrow fibrosis, which could be targeted therapeutically ([@bib30]). Also, Gli1^+^ cells were found to be located in the arterial adventitia in human kidney and associated with vascular calcification of patients with chronic kidney disease ([@bib18]), further indicating that Gli1 is also a useful marker for human MSCs and thus provides a promising target for stem cell-based therapies.

Accumulating findings highlight a perivascular origin of MSCs in broad tissue/organ distribution, despite evidence challenging pericytes as multipotent tissue-resident progenitors ([@bib7]; [@bib9]; [@bib32]). Functionally, the perivascular Gli1^+^ cells, especially those in the skeletal system ([@bib19]; [@bib33]; [@bib44]), have been documented as critical contributors to organ development and injury repair ([@bib30]; [@bib33]; [@bib44]), both of which depend on the vascular system to transport oxygen, nutrients, and circulating cells, as well as carry away waste products ([@bib3]; [@bib29]). Despite the fact that a number of reports on *in vitro* and regenerative applications have shown the promotion of angiogenesis by MSCs ([@bib16]; [@bib25]), it remains poorly understood *in situ* whether MSCs regulate angiogenesis in the perivascular niche. In this study, we revealed that Gli1^+^ cells initiated the neighboring type H vessel angiogenesis in bone growth and healing, therefore providing fundamental insights into the positional-functional correlations of perivascular MSCs. Furthermore, this specific angiogenic regulation may create a distinct metabolic and molecular microenvironment, thus benefiting osteoprogenitors for bone homeostatic maintenance and regenerative repair ([@bib20]; [@bib42]), which further provides mechanistic insights into the bone generation and regeneration processes.

Elucidating cellular and molecular mechanisms regulating type H vessel angiogenesis is of much value for developing approaches to counteract bone loss and enhance bone healing ([@bib20]; [@bib42]). Originally established, type H vessel growth is facilitated by angiocrine release of Noggin regulated by endothelial Notch activity, which is maintained by the miR-497--195 cluster ([@bib28]; [@bib43]). Later on, angiogenic factors secreted by osteoblasts and preosteoclasts, such as C-X-C motif chemokine ligand 9 (CXCL9), Slit homolog 3, and platelet-derived growth factor-BB, have been documented to promote the formation of type H vasculature ([@bib11]; [@bib41]; [@bib42]). The above angiogenic proteins have shown pharmacological potential as osteoanabolic therapies. In addition, a recent study has reported that intermittent parathyroid hormone treatment expands type H ECs and mobilizes perivascular LepR^+^ cells, indicating extrinsic hormonal regulation of type H vessels in relation to MSC-based anti-osteoporotic actions ([@bib4]). Recent studies have also indicated that distinct MSC subsets reside adjacent to type H or type L vessels ([@bib34]), e.g., platelet-derived growth factor receptor beta (PDGFRβ)^+^ and NG2^+^ subpopulations are associated with the type H vasculature ([@bib21]), while the type L sinusoids are surrounded by subpopulations expressing LepR and CXCL12 ([@bib8]; [@bib35]). Nevertheless, while evidence has revealed functional properties of distinct MSC subsets in the regulation of hematopoiesis and osteogenesis, their roles in maintaining vascular homeostasis in relation to their specific locations are less clear ([@bib34]; [@bib35]; [@bib48]). In this study, at the stem cell level, we further revealed that Gli1^+^ cells promote type H vessel angiogenesis during development and regenerative repair, which integrates into the current picture of type H vessel regulation and suggests promising targets for stem cell-based, vasculature-targeted bone regeneration therapies.

Gli proteins are a family of zinc finger transcription factors ([@bib14]) that respond to the hedgehog (HH) signaling pathway and contribute to MSC maintenance ([@bib33]; [@bib45], [@bib44]), e.g., in the adult mouse incisor the released Sonic hedgehog (SHH) protein activates Gli1 expression to safeguard MSC homeostasis ([@bib45]). Accordingly, targeted inhibition of Gli signaling by GANT61 (reported here and by others) attenuates MSC properties ([@bib30]). Through application of GANT61, we further revealed that Gli signaling is involved in the MSC-mediated regulation of angiogenesis. It has also been reported that HIF-1α signaling couples angiogenesis to osteogenesis during skeletal development ([@bib28]; [@bib40]), while HIF-1α also triggers responses of HH signaling and Gli1 protein ([@bib2]; [@bib23]). Previous studies have shown that systemic administration of DFM upregulates type H vessels in bone, and that endothelial HIF-1α signaling promotes type H vessel formation ([@bib20]; [@bib43]). In this study, we revealed that Gli1^+^ cell ablation led to significant downregulation of HIF-1α expression in both bone growth and regeneration, which suggests that Gli1^+^ cells are an important cellular source of HIF-1α signaling. In addition, despite the lack of a Gli1^+^ cell subpopulation, MSCs derived from Gli1^+^ cell ablated mice could still be cultured *in vitro*, suggesting that Gli1^+^ cells exert little effects on the proliferation of MSCs. Nevertheless, the positive effects of DFM on stimulating angiogenesis were significantly restrained, indicating that Gli1^+^ cells represented the critical cellular basis of HIF-1α-mediated type H vessel angiogenesis. Future studies will address the detailed mechanisms underlying the effects of Gli1^+^ cell-derived HIF-1α signaling on the type H endothelium, which might be due to the regulation of vascular endothelial growth factor expression ([@bib40]). It remains interesting to evaluate whether the molecular targets of these processes can be used to prevent tissue degeneration or promote regenerative tissue healing.

In summary, Gli1^+^ cells represent a subpopulation of postnatal MSCs to guide and initiate the formation of neighbored specialized type H vasculature, which supports skeletal development and regeneration. Our findings implicate a link between perivascular localization of MSCs and their angiogenesis-regulatory function, paving the way for stem cell-based, vasculature-targeted osteoanabolic therapies.

Experimental Procedures {#sec4}
=======================

Study Approval {#sec4.1}
--------------

All animal experiments were performed in compliance with the relevant laws and institutional guidelines of the Fourth Military Medical University for Intramural Animal Use and Care Committee and were approved by local animal ethics committees.

Animals {#sec4.2}
-------

The following mouse strains were obtained from the Jackson Laboratory: *Gli1-LacZ* (JAX no. 008211) ([@bib44]), *Gli1-CreER*^*T2*^ (JAX no. 007913) ([@bib30]), *ROSA26-eGFP-DTA* (JAX no. 006331) ([@bib13]), and *ROSA2*6-mT/mG (JAX no. 007676) ([@bib39]). C57BL/6J mice (JAX no. 000664) were used as the wild type. All mice were housed in a pathogen-free condition, maintained on the standard 12-h light-dark cycle, fed with food and water *at libitum*, and used for analyses regardless of sex. Genotyping was performed by PCR as indicated ([@bib5]; [@bib10]), using tail samples from mice and primer sequences provided by the Jackson Laboratory.

For tracing of Gli1^+^ cells in bone histology, *Gli1-LacZ* mice were used at the age of 3--6 weeks (juvenile) and 7--12 weeks (adult) ([@bib20]). For tracing of bone marrow Gli1^+^ cells in flow cytometry, *Gli1-CreER*^*T2*^ and *ROSA2*6-mT/mG transgenics were interbred. For the ablation experiments, *Gli1-CreER*^*T2*^ and *ROSA26-eGFP-DTA* transgenics were interbred ([@bib44]). Cre activities were induced by tamoxifen (Sigma-Aldrich), which was dissolved in corn oil and injected intraperitoneally into offspring at 100 μg/g of body weight every day for 3 days ([@bib28]). For bone defect modeling, defects of 0.7 mm in diameter and approximately two-thirds of the femoral diameter in depth (the other side of the cortical bone remains undamaged) were made in the diaphyseal femoral region using columnar dental diamond burs under general anesthesia ([@bib31]). For skin wound modeling, full-layer cutaneous wounds (10 mm in diameter) were carefully made on the dorsal skin using ophthalmic scissors under general anesthesia ([@bib46]).

Bone Histology and Immunohistochemistry {#sec4.3}
---------------------------------------

Freshly dissected femora were collected and fixed in 4% paraformaldehyde (Sigma-Aldrich, USA) solution for 4 h at 4°C. Decalcification was performed with 0.5 M ethylenediaminetetraacetic acid (MP Biomedicals, USA) under constant shaking for 24 h at 4°C, as described ([@bib22]). Decalcified bone samples were then immersed into 30% sucrose (MP Biomedicals, USA) solution for 24 h, embedded, and frozen in optimum cutting temperature compound, and cryosectioned on a Leica cryostat to get 30-μm-thick sections (CM1950, Leica, Germany).

For immunostaining ([@bib28]; [@bib36]), sections were air-dried, permeabilized in 0.3% Triton X-100 (Sigma-Aldrich, USA) for 20 min, blocked in 5% serum (Sigma-Aldrich, USA) at room temperature for 30 min, and probed with the primary antibodies diluted in blocking serum overnight at 4°C. The primary antibodies were β-galactosidase (ab9361, Abcam, UK; diluted 1:200), CD31 (FAB3628G, R&D Systems, USA; diluted 1:100), EMCN (sc-65495, Santa Cruz Biotechnology, USA; diluted 1:100), CD105 (MAB1320, R&D Systems, USA; diluted 1:100), NG2 (ab5320, Millipore, USA; diluted 1:100), CD146 (ab75769, Abcam, UK; diluted 1:100), SCA1 (ab51317, Abcam, UK; diluted 1:200), RUNX2 (12556, Cell Signaling Technology, USA; diluted 1:200), and HIF-1α (ab179483, Abcam, UK; diluted 1:100). After primary antibody incubation, sections were washed with PBS three times and incubated with appropriate Alexa Fluor-conjugated secondary antibodies (Molecular Probes, USA; diluted 1:400) for 1 h at room temperature. Sections were then washed with PBS three times and nuclei were counterstained with Hoechst 33342 (Sigma-Aldrich, USA) for 30 min at room temperature. After counterstaining, sections were washed with PBS three times and mounted by propanetriol (Sigma-Aldrich, USA).

Image Acquisition and Quantitative Analysis {#sec4.4}
-------------------------------------------

Immunofluorescent staining sections were analyzed using an Olympus laser scanning confocal microscope (FV1000, Olympus, Japan). z stacks of images were scanned at high resolution and were processed and reconstructed in three dimensions with the FV10-ASW Viewer software (version 4.2, Olympus, Japan).

Quantification of images was carried out with Image-Pro Plus (Media Cybernetics, USA) according to previous reports and with some adjustment ([@bib20]; [@bib30]). Specifically, we lined out an area around the vessels with a range of 20 μm ([@bib12]) and quantified the fluorescence signals (parameter: area sum) within this area, which was regarded as the proteins/markers adjacent to type H or type L vessels ([Figure S1](#mmc1){ref-type="supplementary-material"}B). For some indexes, after absolute quantification of the signals, we performed relative quantification by taking the numerical value of one group as the reference and calculating the relative values of other groups, shown as the fold changes.

Statistics {#sec4.5}
----------

All data are represented as mean ± standard deviation (SD). Statistical significance was evaluated by two-tailed unpaired Student\'s t test for two-group comparison, or by one-way analysis of variation (ANOVA) followed by Newman-Keuls post-hoc tests for multiple comparisons in GraphPad Prism version 5.1 (GraphPad, USA). Values of p \< 0.05 were considered as statistically significant.

Data and Code Availability {#sec4.6}
--------------------------

For details of the materials and methods used in this study, please refer to the [Supplemental Information](#app1){ref-type="fn"}.
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